Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Fax: 801 821 2872

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

Spartangio Nov. 14 at 7:47 PM

$RXRX Morgan stanley the one who Decreased our pt? Lol 7,290,353 +30% Rxrx stop diluting now or at least wait some news drop Lest wait for SoftBank within today

0 · Reply

HedgeAlerts Nov. 14 at 6:51 PM

Hedge Alert Live - Protect Your Portfolio Contract: $RXRX $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.09 - $0.15 Exit Price Target: $0.20 Profit Margin: +117% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

1 · Reply

Spartangio Nov. 14 at 6:47 PM

$RXRX Big friends buying and holding Rxrx is diluting too much 20%in November But if big boys stay here… State street corp. 18,268,925shares +65% Mubadala. 12,985,927 Unchanged SoftBank not out yet

0 · Reply

nofunanymore Nov. 14 at 6:36 PM

$RXRX last time at this price was may, fuck this

0 · Reply

nofunanymore Nov. 14 at 6:34 PM

$RXRX down $3.X in 3 fkn weeks

0 · Reply

nofunanymore Nov. 14 at 6:33 PM

$RXRX next move up, I'm out, no catalyst here, tired of fkn around

0 · Reply

nofunanymore Nov. 14 at 5:38 PM

$RXRX

0 · Reply

Bazzzigar Nov. 14 at 5:37 PM

$RXRX HIMS

0 · Reply

garbageshort Nov. 14 at 4:09 PM

$RXRX goes down with AI and then again when XBI goes down

1 · Reply

Hognose Nov. 14 at 3:38 PM

$SSYS $RXRX April lows.

0 · Reply

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 6:30 AM EST - 9 days ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 9 days ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Nov 4, 2025, 8:00 AM EST - 10 days ago

Recursion to Participate in Upcoming Investor Conferences

Oct 28, 2025, 8:00 AM EDT - 17 days ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 22, 2025, 1:42 PM EDT - 23 days ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

Oct 8, 2025, 2:51 PM EDT - 5 weeks ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Sep 8, 2025, 8:03 PM EDT - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 6:51 PM EDT - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 5, 2025, 2:44 PM EDT - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:30 AM EDT - 3 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 3 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 25, 2025, 1:53 PM EDT - 4 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Jul 22, 2025, 7:02 AM EDT - 4 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Jul 8, 2025, 7:10 AM EDT - 4 months ago

What's Happening With RXRX Stock?

Jun 10, 2025, 6:14 AM EDT - 5 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 5 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 5, 2025, 1:37 PM EDT - 6 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 6:00 AM EDT - 6 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:02 AM EDT - 6 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 4, 2025, 12:45 PM EDT - 6 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 7 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 22, 2025, 8:34 PM EDT - 7 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 7 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 7 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Recursion to Participate in Upcoming Investor Conference

Mar 3, 2025, 11:19 AM EST - 9 months ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Feb 28, 2025, 1:16 PM EST - 9 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 6:30 AM EST - 9 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 9 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 9 months ago

Altitude Lab Startups Raise $154M in Capital

Feb 13, 2025, 6:05 PM EST - 9 months ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 5, 2025, 5:24 PM EST - 10 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 7, 2025, 9:15 AM EST - 11 months ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 6, 2025, 8:30 AM EST - 11 months ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Dec 20, 2024, 4:05 PM EST - 11 months ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 12, 2024, 6:07 AM EST - 1 year ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 3:14 PM EST - 1 year ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Nov 20, 2024, 7:00 AM EST - 1 year ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 13, 2024, 9:08 AM EST - 1 year ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 12, 2024, 4:54 PM EST - 1 year ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Oct 30, 2024, 8:22 AM EDT - 1 year ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EDIT EXAS

Oct 2, 2024, 8:32 AM EDT - 1 year ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Sep 4, 2024, 1:03 PM EDT - 1 year ago

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 3, 2024, 8:11 AM EDT - 1 year ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Aug 9, 2024, 9:00 AM EDT - 1 year ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

EXAI

Spartangio Nov. 14 at 7:47 PM

$RXRX Morgan stanley the one who Decreased our pt? Lol 7,290,353 +30% Rxrx stop diluting now or at least wait some news drop Lest wait for SoftBank within today

0 · Reply

HedgeAlerts Nov. 14 at 6:51 PM

1 · Reply

Spartangio Nov. 14 at 6:47 PM

$RXRX Big friends buying and holding Rxrx is diluting too much 20%in November But if big boys stay here… State street corp. 18,268,925shares +65% Mubadala. 12,985,927 Unchanged SoftBank not out yet

0 · Reply

nofunanymore Nov. 14 at 6:36 PM

$RXRX last time at this price was may, fuck this

0 · Reply

nofunanymore Nov. 14 at 6:34 PM

$RXRX down $3.X in 3 fkn weeks

0 · Reply

nofunanymore Nov. 14 at 6:33 PM

$RXRX next move up, I'm out, no catalyst here, tired of fkn around

0 · Reply

nofunanymore Nov. 14 at 5:38 PM

$RXRX

0 · Reply

Bazzzigar Nov. 14 at 5:37 PM

$RXRX HIMS

0 · Reply

garbageshort Nov. 14 at 4:09 PM

$RXRX goes down with AI and then again when XBI goes down

1 · Reply

Hognose Nov. 14 at 3:38 PM

$SSYS $RXRX April lows.

0 · Reply

Floridaorange Nov. 14 at 3:18 PM

$RXRX starter position w/ 2500 shares

1 · Reply

nofunanymore Nov. 14 at 3:11 PM

$RXRX what a dogshit

0 · Reply

bazzjr Nov. 14 at 3:03 PM

$RXRX This is a gem. If it was to be bought out- it’ll be at $4.00- The data, robotics and tech it has is far more valuable whether they make it or no. This is a 5-10 year play if biology becomes programable which RXRX is working on atm- This will be a Nvidia type play.. If they fail- kiss our money good bye but I believe it will make it happen with AI.

0 · Reply